A more effective HER2-targeting peptide drug conjugate is needed for breast cancer treatment.

Published Date: 17 May 2023

Target specificity, a broad therapeutic indices, and a prolonged circulation half-life are all benefits of antibody-drug conjugates (ADCs). The large size (?150 kDa), which noticeably slows, is an important drawback of ADCs, though.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Studies have shown that physical activity prevents cancer in patients who have been treated for cancer in the past.

2.

New policy review highlights the importance of health-related quality of life in advanced cancer

3.

In myelofibrosis, combinations of rufolitinib reduce spleen volume.

4.

Better treatments buoy multiple-myeloma patients, bound by research cuts and racial disparities

5.

More Data from Population-Based Studies Show CRC Screening Lowers Cancer Death Risk.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot